Join

Compare · ABBV vs VHAQ

ABBV vs VHAQ

Side-by-side comparison of AbbVie Inc. (ABBV) and Viveon Health Acquisition Corp. (VHAQ): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABBV and VHAQ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABBV is the larger of the two at $351.47B, about 1390.2x VHAQ ($252.8M).
  • ABBV has hit the wire 9 times in the past 4 weeks while VHAQ has been quiet.
  • ABBV has more recent analyst coverage (25 ratings vs 0 for VHAQ).
MetricABBVVHAQ
Company
AbbVie Inc.
Viveon Health Acquisition Corp.
Price
$198.71-1.12%
$11.30+0.00%
Market cap
$351.47B
$252.8M
1M return
-4.09%
-
1Y return
+3.29%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
AMEX
IPO
2012
2021
News (4w)
9
0
Recent ratings
25
0
ABBV

AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

VHAQ

Viveon Health Acquisition Corp.

Viveon Health Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Norcross, Georgia.

Latest ABBV

Latest VHAQ